We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock

Delisted

PRVB was delisted on the 26th of April, 2023.

112 hedge funds and large institutions have $133M invested in Provention Bio, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

177% more call options, than puts

Call options by funds: $4.5M | Put options by funds: $1.63M

8% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 37

9% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 22

3% less funds holding

Funds holding: 115112 (-3)

7% less capital invested

Capital invested by funds: $143M → $133M (-$10M)

Holders
112
Holders Change
-3
Holders Change %
-2.61%
% of All Funds
1.72%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
34
Reduced
37
Closed
22
Calls
$4.5M
Puts
$1.63M
Net Calls
+$2.87M
Net Calls Change
+$1.58M

PRVB Hedge Fund Activity: Q4 2021 in Review

112 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q4 2021, worth a combined $133M — down 7% from $143M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of PRVB and 20 opened new positions — a net loss of 2 holders — while 37 trimmed existing stakes and 34 added.

The largest buyer was Sessa Capital, adding an estimated $10.8M. The largest seller was Millennium Management, cutting an estimated $1.51M.

  • 112 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q4 2021, down from 115 in Q3 2021.
  • Funds reported $133M of Provention Bio, Inc. Common Stock stock for Q4 2021, down 7% quarter-over-quarter.
  • 20 funds opened new Provention Bio, Inc. Common Stock positions in Q4 2021 and 22 closed out, a net change of -2 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q4 2021 was Sessa Capital, an estimated $10.8M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $1.51M sold.

Based on aggregated 13F filings for Q4 2021.